chartexchange

4D Molecular Therapeutics Reports Q3 2026 Revenue of $4.1 Million, Net Loss of $78. ...

GuruFocus | Nov 12, 2026 6:00 PM EST

Late-stage gene therapy developer advances two pivotal wet AMD trials and launches a Phase 3 DME program while holding $375 million in cash Related Stocks: FDMT ,

Read original article